Browsing by Author "Sunanta Chariyalertsak"

Now showing 1 - 2 of 2
  • Default Image
    Item
    Hypermethylation of suppressor of cytokine signaling 1 in hepatocellular carcinoma patients
    (Asian Pacific Organization for Cancer Prevention, 2012) Pensri Saelee; Ubol Chuensumran; Sopit Wongkham; Sunanta Chariyalertsak; Danai Tiwawech; Songsak Petmitr; P. Saelee; Research Division, National Cancer Institute, Bangkok, Thailand; email: saelee@health.moph.go.th
    Hepatocellular carcinoma (HCC), the most common primary hepatic tumor, is highly prevalent in the Asia-Pacific region, including Thailand. Many genetic and epigenetic alterations in HCC have been elucidated. The aim of this study was to determine whether aberrant methylation of the suppressor of cytokine signaling 1 gene (SOCS1) occurs in HCCs. Methylation specific-PCR assays were performed to identify the methylation status of SOCS1 in 29 tumors and their corresponding normal liver tissues. An abnormal methylation status was detected in 17 (59%), with a higher prevalence of aberrant SOCS1 methylation significantly correlating with HCC treated without chemotherapy (OR=0.04, 95%CI=0.01-0.31; P=0.001). This study suggests that epigenetic aberrant SOCS1 methylation may be a predictive marker for HCC patients.
  • Default Image
    Item
    RASSF1A promoter hypermethylation as a prognostic marker for hepatocellular carcinoma
    (Asian Pacific Organization for Cancer Prevention, 2010) Pensri Saelee; Sopit Wongkham; Sunanta Chariyalertsak; Songsak Petmitr; Ubol Chuensumran; P. Saelee; Research Division, National Cancer Institute, Bangkok, Thailand; email: saelee@health.moph.go.th
    This study was performed to determine whether epigenetic aberrant methylation of RASSF1A might be associated with hepatocarcinogenesis. Methylation specific-PCR was performed to identify RASSF1A promoter hypermethylation in 29 tumors and corresponding normal liver tissues. In addition, RASSF1A mRNA levels were analyzed by quantitative real-time reverse transcription-PCR. Aberrant methylation of RASSF1A was detected in 25 of 29 cases (86%), with loss of RASSF1A expression evident in 8 of 22 cases (36%). No correlation between loss of RASSF1A mRNA and promoter hypermethylation of the RASSF1A gene was observed. There was a significant correlation between the methylation status of RASSF1A and hepatocellular carcinoma (HCC) patients who did not undergo chemotherapy (P = 0.03). Multivariate analysis, adjusted for tumor size, treatment, RASSF1A hypermethylation, and RASSF1A under-expression, showed RASSF1A hypermethylation to be assocaited with a better prognosis for HCC patients (HR= 0.089, 95%CI = 0.013-0.578; P = 0.012). Our findings showed that RASSF1A promoter hypermethylation occurs frequently, and may serve as a good prognostic factor.